Abstract: Tyrosine kinase inhibitors(TKIs) targeting the BCR-ABL1 oncoprotein make patients who have diagnosed with chronic phase(CP) chronic myelocytic leukemia(CML) live long-term survival. Many patients may encounter adverse events usually occur early after treatment initiation which are mild to moderate in intensity and resolve spontaneously, or are easily controlled with adequate supportive care. However, long-term safety issues have not been fully elucidated at present, especially for new-generation TKIs. Recent evidence has emerged that these new agents may sometimes impinge on the heart and lung in an irreversible. review relevant TKIs adverse reactions as well as its management.